Evaluation of reporting quality of abstracts of randomized controlled trials regarding patients with COVID-19 using the CONSORT statement for abstracts

• Published in: International journal of infectious diseases 2022-03, Vol.116, p.122-129
• Main Authors: Yin, Yuhuan, Gao, Jiangxia, Zhang, Yiyin, Zhang, Xiaoli, Ye, Jianying, Zhang, Juxia
• Format: Article
• Language: English
• Subjects: COVID-19; Patients; Randomized controlled trial abstracts; Reporting quality; The CONSORT statement for abstracts
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2022.01.002

•The reporting quality of the abstracts of randomized controlled trials on patients with COVID-19 was evaluated.•Factors influencing the quality of reporting were analyzed.•To provide reliable evidence for meta-analysis of RCTs related to COVID-19 patients. To evaluate the reporting quality of randomized controlled trial (RCT) abstracts regarding patients with coronavirus disease 2019 (COVID-19) and to analyze the factors influencing the quality. The PubMed, Embase, Web of Science, and Cochrane Library databases were searched to collect RCTs on patients with COVID-19. The retrieval time was from inception to December 1, 2020. The CONSORT statement for abstracts was used to evaluate the reporting quality of RCT abstracts. A total of 53 RCT abstracts were included. The CONSORT statement for abstracts showed that the average reporting rate of all items was 50.2%. The items with a lower reporting quality were mainly the trial design and the details of randomization and blinding (